Price Chart

Profile

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
URL http://www.climbbio.com
Investor Relations URL https://ir.climbbio.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release Aug. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
URL http://www.climbbio.com
Investor Relations URL https://ir.climbbio.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release Aug. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A